At Johnson & Johnson, we value transparency as a key component of trust building with all those engaged in any way with our business. We strive to hold ourselves accountable by providing information about how we operate across our operating companies and markets. We recognize and comply with the multiple reporting requirements that regulatory bodies governing our three business segments define and, in addition, we publish a wide range of other regulatory and voluntary disclosures. See our Position on Transparency.
Pricing transparency in the United States: We publish our annual Janssen U.S. Transparency Report that includes how we invest our resources, price our medicines, and help people who need Janssen medicines gain access to them. See the latest Report here.
Improving clinical data transparency: Johnson & Johnson was a key contributor to documents on clinical data transparency and patient privacy that were first developed and shared through TransCelerate Biopharma, a nonprofit that encourages collaboration across the biopharmaceutical community to streamline and accelerate the R&D of innovative new therapies. Now, this evolving guidance is accessible to an even broader global community. In June 2019, a TransCelerate working group transferred two “living documents” to PHUSE, a nonprofit, volunteer-supported community of pharmaceutical industry colleagues. PHUSE provides collaboration tools and resources to encourage worldwide interaction. Its members include data managers, biostatisticians, statistical programs and eClinical IT professionals. Janssen colleagues are active in PHUSE, and played a leading role in organizing PHUSE’s 2019 conference in the United States.
Responding to concerns about opioids: Johnson & Johnson is committed to ensuring its medicines are used correctly, including by providing important information about their risks and benefits on every product label. Responsibly used, opioid- based pain medications play a critical role in helping doctors and patients manage the debilitating effects of serious pain, and the Company’s pain medicines were designed to prevent and deter abuse with some of the lowest rates of abuse among prescription opioid pain medicines. The Janssen Pharmaceutical Companies of Johnson & Johnson no longer develop or promote opioid-based pain medicines, and since 2008, the volume of its prescription opioids has amounted to less than one percent of the total prescriptions written per year for opioid medications in the United States.